|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||128.05 - 132.40|
|52 Week Range||105.00 - 164.15|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||55.90|
|Forward Dividend & Yield||0.70 (0.55%)|
|Ex-Dividend Date||May 28, 2020|
|1y Target Est||N/A|
A broad moat, multi-cylinder growth engine and recurring revenue model shed light on long-term shareholder value of the software business Continue reading...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
U.S. and European defence firms backed Indian Prime Minister Narendra Modi's military modernisation drive at a defence exhibition on Friday, despite a lengthy procurement process running into years and limited funds. Airbus SE and U.S.-based Lockheed Martin Corp and Boeing Co. are eying multi-billion dollar deals under Modi's aim to upgrade an ageing fleet of aircraft and enhance local arms manufacturing to cut imports.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Analyzing Dassault Systèmes SE's (ENXTPA:DSY) track record of past performance is a valuable exercise for investors...
France has enlisted tech companies Dassault Systemes and OVH to come up with plans to break the dominance of U.S. companies in cloud computing, its finance minister said on Thursday. Paris is eager to build up a capacity to store sensitive data in France amid concerns the U.S. government can obtain data kept on the servers of U.S. companies such as Amazon and Microsoft.
FRANKFURT/BERLIN, Sept 5 (Reuters) - Private equity firm KKR is preparing for a stock market flotation or sale of German defence supplier Hensoldt in a potential 2 billion euro ($2.2 billion) deal, people close to the matter said. The buyout group has in recent weeks listened to bankers present options for exiting its investment, including a listing of 20-30% on the stock exchange or a sale to a defence group or private equity business next year, they said, adding KKR was expected to hire an adviser soon to help arrange a deal. KKR declined to comment.
FRANKFURT/BERLIN, Sept 5 (Reuters) - Private equity firm KKR is initiating preparations for a stock market flotation or sale of German defence supplier Hensoldt in a potential 2 billion euro ($2.2 billion) deal, people close to the matter said. The buyout group has in recent weeks listened to bankers present exit options, including a listing of 20-30% on the stock exchange or a sale to a defence group or private equity investor next year, they said, adding that KKR is expected to soon mandate an advisor to help organise the deal. KKR declined to comment.
In 2002 Bernard Charlès was appointed CEO of Dassault Systèmes SE (EPA:DSY). This analysis aims first to contrast CEO...
Today we'll evaluate Dassault Systèmes SE (EPA:DSY) to determine whether it could have potential as an investment...
shares traded lower Wednesday after it agreed a takeover offer from France's Dassault Systemes SE at a discount to its current market value. Dassault said it would pay $92.25 for each Medidata share in a deal that values the New York-based group at $5.8 billion. "Today marks a significant milestone for the Life Sciences industry and the value of the virtual world to address the complexity of developing personalized medicine and patient-centric experiences," said Dassault CEO Bernard Charles.
(Bloomberg) -- French technology company Dassault Systemes SE agreed to buy Medidata Solutions Inc., a software firm that analyzes clinical trials, for $5.7 billion to bolster its offerings to the pharmaceutical industry.The record deal will allow Dassault to offer drugmakers a complete set of services and ride a shift toward personalized medicine, in which research and tools are tailored to individual patient profiles, generating the need to analyze vast amounts of data.Health is becoming a crucial market for Dassault, which also creates 3D design software, said Pascal Daloz, the company’s chief financial officer. Medidata offers clients wearable sensors that help track patients’ health in real life and biomarker analysis to select which ones may best respond to drugs. It estimates that 13 of the top 15 medicines sold last year relied on its technology.“This is by far the largest acquisition we’ve ever made,” Daloz said on a conference call, highlighting Dassault’s interest in the health market.Drugmakers’ CostsThe all-cash transaction values Medidata at $92.25 a share -- 17% more than Medidata’s closing price on April 18, the last trading day before Bloomberg reported Dassault’s interest in the New York-based company. Medidata shares were down 3.5% to $91.45 at 9:59 a.m. in New York. Dassault fell 1.5% to 134.45 euros in Paris.The deal is expected to close in the final quarter of 2019 and start boosting earnings as early as 2020, the companies said in a statement.Drugmakers faced with rising development costs are outsourcing many parts of their research and development efforts, using specialized providers of services and technology.Medidata counts most of the biggest drug companies in the world as customers, according to supply-chain data compiled by Bloomberg. It provides a cloud-based subscription service that helps medical device, diagnostic and pharmaceutical companies manage and analyze clinical trials. Its revenue more than doubled from 2013 to 2018, when it brought in $635.7 million.Dassault, with a market value of 36 billion euros ($41 billion), offers software and services for industries ranging from aerospace and defense to consumer goods. The life sciences business counts many major pharma companies among its clients.The planned acquisition, endorsed by both boards, marks the first time the French company has resorted to external funding, according to Daloz. Dassault will finance the takeover with a 1 billion-euro loan, a 3 billion-euro bridge-to-loan facility and available cash.(Updates with Dassault shares in sixth paragraph.)\--With assistance from Liana Baker, Geraldine Amiel and Marie Mawad.To contact the reporters on this story: Ed Hammond in New York at firstname.lastname@example.org;Ruth David in London at email@example.com;Manuel Baigorri in Hong Kong at firstname.lastname@example.orgTo contact the editors responsible for this story: Elizabeth Fournier at email@example.com, ;Giles Turner at firstname.lastname@example.org, Jeff Sutherland, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.